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Dear Colleagues,
World Diabetes Day is celebrated annually on No-
vember 14 — the birthday of Frederic Banting. Each 
year World Diabetes Day carries a particular theme to 
bring the public’s attention to the various aspects of the 
disease. This year was celebrated in Poland under the 
slogan “Woman and man. Does diabetes have a gen-
der?” paying particular attention to gender-related 
differences in the course of the disease. 
Therefore, the current issue of “Clinical Diabeto-
logy” includes papers addressing currently discussed 
problems concerning both women and men with 
diabetes. In this respect, it is worth noting the original 
article on the important but sometimes overlooked 
aspect of the everyday life of people with diabetes, 
which is sexual dysfunction. The authors assessed the 
satisfaction of the sexual life of patients with diabetes, 
emphasizing that it is an important component of 
the well-being of each patient, regardless of gender. 
Another interesting article discussing gender-related 
problems is the original paper on nutritional choices 
in pregnant women, including those with gestational 
diabetes whose incidence is constantly increasing. The 
paper indicates that the type of diet appears to be 
a significant contributing factor. 
However, regardless of gender, diabetes increases 
cardiovascular risk, and therefore antidiabetic drugs 
are not only required to be effective in lowering blood 
glucose but also provide cardiovascular safety, i.e. they 
are expected to not increase the risk of cardiovascular 
events, or even to reduce it. Following the publication 
of the results of already completed Cardiovascular 
Outcome Trials (CVOTs) on new molecules used in 
the treatment of diabetes, there is no doubt that 
we have drugs that have protective effect on the 
cardiovascular system, of which empagliflozin and 
liraglutide additionally reduce cardiovascular morta-
lity. However, practitioners are expecting with great 
interest the results of trials assessing other molecules 
including another SGLT2 inhibitor — dapagliflozine. 
Therefore, the current issue includes an article about 
the effect of this molecule on the cardiovascular sys-
tem. A large multicentre, randomized, double-blind, 
placebo-controlled phase IIIB trial with dapagliflozin, 
DECLARE-TIMI58 (Dapagliflozin Effect on Cardiovas-
cuLAR Events), is under way. The study aims to assess 
cardiovascular risk and is scheduled to be completed 
in 2019. Its results will answer the question whether, 
in terms of cardiovascular risk, there is a class effect 
of SGLT2 inhibitors. 
As usual, I invite you not only to read, but also to 
actively contribute to our journals, “Clinical Diabeto-
logy” and “Diabetologia Praktyczna”, by submitting 
interesting papers and comments on the topics dis-
cussed by other authors. 
Editor-in-Chief
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